Quantedge Capital’s Ascendis Pharma A/S ASND Stock Holding History

Quantedge Capital’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,000	Closed	-$2.52M	–	52
2026 Q1	$2.52M	Buy	11,000 +1,800	+20%	+$404K	1.38%	16
2025 Q4	$1.96M	Buy	9,200 +2,100	+30%	+$434K	0.93%	24
2025 Q3	$1.41M	Buy	+7,100	New	+$1.32M	0.77%	26

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Quantedge Capital's ASND Position: Q2 2026 in Review

Quantedge Capital sold out of Ascendis Pharma A/S (ASND) in Q2 2026, closing a stake of 11,000 shares — an estimated $2.52M sold.

Quantedge Capital first reported a position in ASND in Q3 2025 and held it in 3 quarters. The position peaked at $2.52M in Q1 2026. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Quantedge Capital reported no remaining Ascendis Pharma A/S position as of Q2 2026 after selling out during the quarter.
Quantedge Capital sold 11,000 Ascendis Pharma A/S shares in Q2 2026, an estimated $2.52M.
Quantedge Capital first reported a position in Ascendis Pharma A/S in Q3 2025 and held it in 3 quarters.
Quantedge Capital's Ascendis Pharma A/S position peaked at $2.52M in Q1 2026.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Quantedge Capital's 13F filing for Q2 2026, filed 6 Aug 2026.